Published 2 September 2008, doi:10.1136/bmj.a985
Cite this as: BMJ 2008;337:a985

Editorials

Direct to consumer advertising of prescription drugs

Even attenuated forms such as cross border advertising can lead to unnecessary harm

The first 150 words of the full text of this article appear below.

Are there public health consequences when regulators turn a blind eye to cross border advertising that contravenes national laws? Although Canada prohibits direct to consumer advertising of prescription drugs, no steps are taken to prevent US advertising from reaching the Canadian public. The linked study by Law and colleagues (doi: 10.1136/bmj.a1055), provides compelling evidence that this does have consequences for public health and of the need for better regulatory oversight.1

Direct to consumer advertising from the United States reaches Canadians via cable television and US magazines sold in Canada. Law and colleagues found that cross border advertising increased prescribing of a minimally effective drug with a poor safety profile,2 which subsequently led to its withdrawal.3

French speaking Canadians, who mainly live in Quebec, watch less US television than their English speaking compatriots and are less exposed to US direct to consumer advertising. Law and colleagues used this difference to . . . [Full text of this article]

Barbara Mintzes, assistant professor, therapeutics initiative

1 Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada V6T 1Z3

bmintzes@chspr.ubc.ca


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

In search of equity
Fiona Godlee
BMJ 2008 337: a1554. [Extract] [Full Text]

Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study
Michael R Law, Sumit R Majumdar, and Stephen B Soumerai
BMJ 2008 337: a1055. [Abstract] [Full Text] [PDF]

Selling sickness: the pharmaceutical industry and disease mongering Commentary: Medicalisation of risk factors
Ray Moynihan, Iona Heath, David Henry, and Peter C Gøtzsche
BMJ 2002 324: 886-891. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Direct Consumer Advertising
Edzard Ernst
bmj.com, 5 Sep 2008 [Full text]



Access jobs at BMJ Careers
Whats new online at Student 

BMJ